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Non-union of a fracture is a phenomenon that may complicate bone healing. Consolidation of a fracture
can be divided into three phases: inﬂammation, reconstruction, and remodeling. Both the complement
system and the coagulation cascade interact at various steps throughout these phases. Several com-
plement components are speciﬁcally associated with the inﬂammation phase of bone healing. However,
in which way complement components inﬂuence the remodeling phase has not been established yet.
Mannose-Binding Lectin (MBL) and its associated serine protease MASP-2 (Mannanbinding lectin serine
protease-2) are important initiating proteins of the complement system and have also been implicated in
coagulation. With respect to the characteristics and interactions of MBL, it is likely to assume a
considerable inﬂuence of MBL in the remodeling phase of bone healing. A deﬁciency in MBL then, caused
by a genetic variation, may disturb this particular process during bone healing, due to either an accu-
mulation of apoptotic cells or to a diminished scaffold of ﬁbrin molecules. The next step would be early
identiﬁcation of patients with a deﬁciency of MBL, allowing for early therapeutic intervention or even
non-union preventive measures. This review aims to discuss the true and hypothesized role of MBL in
bone healing and the consequences of a depletion of the protein in the etiology of fracture non-union.
 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Mannose-Binding Lectin (MBL) is a protein of the innate im-
mune system, involved in neutralizing a multitude of pathogens.
With reported incidences of up to 40% in Caucasian populations, a
deﬁcit of functional MBL is one of the most common immunode-
ﬁciencies.1 The resulting variation in MBL blood levels in the pop-
ulation has been shown to play a role in the manifestation of a
number of diseases and complications. MBL and its associated
proteinase MASP-2 (Mannan-binding lectin serine protease) play
multiple roles in the different stages that occur during bone frac-
ture healing: inﬂammation, reconstruction and remodeling. In this
review we will discuss the arguments for the potential relation of
MBL and MASP-2 with failure of fracture healing. This so called
fracture non-union is one of the most frequent complications in the
treatment of long bone fractures, with rates ranging from 5% to 30%
or even higher.2 Non-union of a fracture causes signiﬁcant impact
on the patient due to persistent disability, gait abnormality, and
prolonged physical and psychological disability.3 Treatment of a
non-union long-bone fracture is estimated to cost an averageiden University Medical Cen-
J. Van der Ende), C.F.M.Sier@
ciates Ltd. Published by Elsevier Lt20.000 euro, when both direct medical costs and indirect costs (lost
wages, impairments) are calculated.4 This is a “best-case scenario”
where healing is expected within 6 months after non-union
treatment. Screening trauma patients with a bone fracture for
MBL-deﬁciency could allow for early therapeutic and preventive
measures, preventing the development of non-union. We will ﬁrst
focus on the functions of MBL in the cross-talk between the com-
plement system and the coagulation cascade, which both have an
extensive role in fracture healing. Then we discuss how MBL me-
diates the deletion of apoptotic cells, an essential process during
fracture healing.
2. Clinical relevance of MBL
In the past two decades, the role of MBL in the elimination of
pathogens has been studied extensively and its implication in the
etiology of several diseases has been recognized. For instance,
diminished levels of MBL demonstrate an association with a pre-
disposition to HIV-1 infections.5 Low serum levels of MBL are also
associated with enhanced atherosclerosis and coronary artery
disease, indicating that normal or higher MBL levels prevent the
evolution of atherosclerotic plaques, expressed in decreased
numbers of myocardial infarction.6 On the other hand, patients
recovering on the intensive care unit demonstrate a better outcome
when low levels or a complete deﬁciency of MBL are present.7 In
the phase following tissue hypoxia, higher local levels of MBLd. All rights reserved.
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response to the oxidative stress, that can result in additional
damage to the tissue.8 TheMBL deﬁciency in patients with Systemic
Lupus Erythematosus (SLE) may be due to the presence of high
numbers of anti-MBL antibodies.6,9 In a case report that described
the occurrence of fracture non-union in patients with SLE, the au-
thors suggested that non-union could be based on the presence of
so-called ubiquitous antigens at the fracture site. A low level of MBL
in SLE patients indicates a reduction in the removal of antigens
including ubiquitous antigens. Therefore, in this case report, low
MBL levels may have been associated with non-union of a
fracture.10
These examples demonstrate that depending on the disease the
level of MBL, either when raised, normal, or diminished, may
induce either amelioration or damage to the patient.11 Translating
this knowledge to the process of fracture healing, it would be
comprehensible to hypothesize that an altered level of MBL may
inﬂuence the process in which the two fractured ends proximate
and consolidate.
3. The activities of Mannose-Binding Lectin
3.1. Complement
The immune system eliminates macromolecules, invades
pathogens, alters host cells, and eliminates apoptotic cells. The
acquired part of the immune system constitutes adapted defense
mechanisms while the more primitive non-speciﬁc part of defense,
called innate immunity, is initiated and characterized primarily by
pattern recognition molecules including ﬁcolin and MBL. MBL is a
complement protein that is part of the complement cascade and as
a member of the collectin family MBL is predominantly synthesized
by the liver. The complement cascade contains over 30 different
plasma and cell-surface proteins that are involved in three different
pathways: the classical, the alternative, and the lectin pathway.12
All three pathways merge at the level of the complement protein
C3 that has a key-role in the opsonization and lysis of pathogens
(Fig. 1). Through the complement cascade innate immunity is
considered to be the ﬁrst barrier to infection, based on recognition
of so called pathogen associated molecular patterns (PAMPs) that
are expressed on infectious agents.13 Recently, antigens that are
exposed on human cells after a stressful event, such as shock andFig. 1. Schematic representation of the interaction of MBL within the complement and
coagulation cascades.reperfusion, were added to this spectrum of PAMPs, indicating that
the innate immune system is also able to recognize self-antigens.7
Damaged cells or cells that have received apoptotic signals from
surrounding cells present altered proteins and phospholipids on
their cell surface as a signal for elimination. Subsequent binding of
MBL to these recognitionmolecules on the surface of apoptotic cells
results in phagocytosis of the apoptotic cell and successive elimi-
nation from the surrounding by macrophages.14 In addition, mac-
rophages have been shown to produce MBL, facilitating the process
of apoptosis.15 As an overall result, MBL facilitates in the clearance
of a multitude of pathogens including mycobacterium, fungi, par-
asites, prions, bacteria, and viruses, but also of self-antigens
including apoptotic cells.16
MBL activates the complement cascade after binding to carbo-
hydrate structures in a particular geometry and density on the cell
membrane.17 After binding, MBL undergoes a conformational
change that converts MBL-associated serine proteases (MASPs) to
their active forms that subsequently activate a cascade of comple-
ment proteins (Fig. 1). Three MASPs (MASP-1, MASP-2, and MASP-
3) are the key initiators of the lectin pathway of the complement
cascade. After binding to MBL they recognize, cleave, and activate
complement proteins C2 and C4, generating the complement
convertase C4b2a. Cleavage of the complement proteins C3 and C5
produces C3a and C5a, two pro-inﬂammatory anaphylotoxins that
cause degranalution of inﬂammatory cells (includingmast cells and
phagocytes), and induce an inﬂammatory response at the site of
complement activation. In addition, C3b, the other cleavage prod-
uct of C3, induces opsonization of the target cell when deposited on
the cell surface in order to be phagocytized. Therefore, at the end,
the cascade that started with binding of MBL, ﬁnally results in
opsonization of the target cell.
3.2. Coagulation
Activation of the complement system is tightly connected to
hemostasis.18 Coagulation is regulated by the thrombin-induced
cleavage of ﬁbrinogen to ﬁbrin and activation of platelets and fac-
tor XIIIa following cleavage of factor XIII. The activated factor XIIIa
cross-links ﬁbrin to the surface of a pathogen, resulting in an
extended network of ﬁbrin-molecules, which are able to bind
MBL.19 A key protein in the activation of coagulation is factor Xa,
activating thrombin through cleavage of prothrombin. Recently it
has been demonstrated that MASP-2 cleaves prothrombin even
more efﬁciently, resulting in more activated thrombin molecules
that cleave ﬁbrinogen to ﬁbrin molecules (Fig. 1).20,21 The ﬁbrin
network stabilizes complexes between MBL and MASP when
bound to the surface of the same pathogen. This stabilization
augments the activation of the MASPs and increases the subse-
quent activation and deposition of the complement proteins C4, C2,
and C3, with augmentation of the complement-cascade as a
result.19 The formation of a network of ﬁbrin is actually the very
ﬁrst step of fracture healing. Therefore, in addition to its role in
phagocytosis of apoptotic cells, MBL may have an important role in
initiating fracture repair by initiating the coagulation cascade. A
deﬁciency in MBL blood levels may compromise this process.
4. Mannose-Binding Lectin deﬁciency
MBL deﬁciency results from single nucleotide polymorphisms
(SNP’s) in the gene coding for MBL.16 This variation in coding
sequence results in signiﬁcant inter-individual variations in MBL
plasma concentrations. In heterozygous genotypes this can result in
an 85e90% decrease of MBL functional activity. Genotypes homo-
zygous for the mutation may be completely depleted from func-
tional MBL.11 The prevalence of mutations in the MBL variant allele,
J. Van der Ende et al. / International Journal of Surgery 11 (2013) 296e300298
REVIEWas obtained from a Danish population, demonstrated 36% of the
population being heterozygous for the mutation and 4% being ho-
mozygous.1 In addition to a decreased level of functional MBL,
variant alleles can produce MBL molecules with an intrinsic
decreased function.14 Regarding the role of MBL in the complement
cascade and coagulation cascade a shortage or a dysfunction in this
protein will affect the outcome of one or both cascades. A lower
quantity of MBL will bind to smaller numbers of ﬁbrin molecules,
with a diminution in the deposition of the complement protein C3
as a result.20 A decreased deposition of C3 as the key protein of the
complement cascade may reduce the number of opsonized path-
ogens. Moreover, a reduced activation of thrombin results in
reduced amounts of ﬁbrinopeptide A (FPA) and ﬁbrinopeptide B
(FPB), two additional cleavage products of ﬁbrinogen.22 The che-
moattractants FPA and FPB play an essential role in the recruitment
of neutrophils, ﬁbroblasts, and macrophages to the site of ﬁbrin-
ogen turnover in early immune activation.20,21 Reduced numbers of
macrophages results in reduced interaction with ﬁbroblasts, oste-
oblasts, and osteoclasts, the cells responsible for formation and
resorption of mesenchymal tissue that have a strong inﬂuence on
the outcome of fracture healing.
The association of diminished levels of MBL and a decreased
susceptibility to infectious disease and autoimmune disorders may
be subject to selective advantage that supports heterozygosity of
the variant MBL allele.23 As a result, in speciﬁed populations
throughout the world the incidence of the heterozygous variant
MBLmolecule is enhanced. For example, in an African environment
where the burden of infectious disease is high, a mutation associ-
ated with MBL deﬁciency demonstrated a selective advantage.24
HIV-positive patients partly deﬁcient for MBL demonstrated a sig-
niﬁcant slower rate of disease progression compared to HIV-
positive patients with normal MBL serum levels.25 In sub-Saharan
populations nearly 60% has an allele causing MBL deﬁciency, sug-
gesting it may provide protection against frequently encountered
intracellular pathogens as the tuberculosis bacteria.23 Therefore,
due to selective advantage, the number of MBL-deﬁcient people is
most probable still increasing.
5. The implication of MBL in fracture healing and non-union
Fracture healing is the process of bone repair that eventually
results in fracture consolidation and in which three phases can be
identiﬁed: inﬂammation, reconstruction, and remodeling, consecu-
tively demonstrated in Fig. 2.26Fig. 2. Overview of the role of MBL in bone healing. MBL interacts at various steps in
three phases of bone healing. In the inﬂammation phase MBL activates thrombin with
subsequent activation of the coagulation cascade. In the reconstruction phase MBL
activates the complement cascade and induces the formation of callus following
activation of ﬁbrin molecules. Finally, in the remodeling phase, MBL induces apoptosis
through opsonization by the complement cascade.5.1. Inﬂammation phase
The ﬁrst phase of fracture repair, the inﬂammatory period, is
characterized by the onset of a hematoma at the fracture site (Fig. 2,
ﬁrst section). Blood vessels within and around the cortex are
ruptured during trauma and leave the fracture site deprived of
oxygen. Following tissue hypoxia numbers of inﬂammatory cells
will increase at the fracture site. The inﬂammatory cells secrete
mediators and chemo-attractants to keep viable osteoprogenitor
cells alive in the deprived surrounding and to induce migration of
mesenchymal stem cells to the site of the developing blood clot.
This blood clot at the fracture site is the outcome of the coagulation
cascade with MBL and MASP-2 as key proteins, serving as a tem-
porary extracellular matrix to scaffold platelets, leukocytes, and
mesenchymal stem cells.
5.2. Reconstruction or hypertrophic phase
The invasion of the blood cloth with ﬁbrovascular tissue induces
formation of a combination of ﬁbrous composites, cartilage, and
bone that will expand to a fracture-bridging structure named
callus. Although the constitution differs essentially from normal
bone, callus-formation implies the second phase of bone repair and
can best be described as hyperplasia of osteoprogenitor cells be-
tween both fractured ends (Fig. 2, second section). For complete
consolidation of the fracture, degradation of part of the callus is a
required step.
5.3. Remodeling or apoptotic phase
In order to balance the number of osteoprogenitor cells during
the hypertrophic phase, apoptosis is a major process during the
remodeling phase (Fig. 2, third section).27 Apoptosis depends on
many variables including inﬂammatory cell signaling, circulating
immune complexes, and complement activation by MBL-MASP as
described before. The apoptotic process is characterized by cyto-
plasmic and nuclear condensation and formation of apoptotic
bodies, all processed within the cell. They therefore do not trigger
an inﬂammatory response. As a result, adjacent cells will not suffer
from damage induced by inﬂammation. However, apoptotic cells do
demonstrate an altered exposure of phospholipids on their cell
membrane that, together with an altered integrity of the mem-
brane, can be recognized by adjacent cells.17 Macrophages recog-
nizing opsonized cell membranes can engulf the apoptotic cell,
either through phagocytosis or macropinocytosis. An important
step within this recognition process is the MBL-MASP-induced
complement activation. Described apoptotic modiﬁcations have
been observed in osteoblasts during callus remodeling as part of
fracture consolidation.27
The time needed for each phase of fracture consolidation varies
considerably between patients and is found to depend on variables
as patient’s age, site of fracture, type of fracture, nutrition and
comorbidities such as diabetes, obesitas, and rheumatic arthritis.3
Known risk factors for a decreased consolidation are inadequate
stabilization of the fracture, poor blood supply, an infection at the
fracture site, smoking, alcohol and the use of certainmedication.3,28
Each of these factors and their combinations are known to attribute
to impaired fracture healing and may ﬁnally result in the deﬁnitive
failure of the fracture to consolidate: a non-union.
MBL-mediated opsonization and successive phagocytosis is the
leading pathway of elimination of apoptotic cells by the innate
immune system.29 Phagocytosis is increased in a MBL dose-
dependent manner with the consequence that a deﬁciency of
MBL results in a continuing presence of apoptotic bodies at the
fracture site that may prevent the fracture from consolidation.30
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removal of the apoptotic cells in relation to non-union has not been
described before. As already demonstrated in previous studies,
complement proteins are involved in the remodeling phase of bone
healing. However, which complement protein is directing this
process has not yet been elucidated.31 Regarding the discussed
characteristics of MBL and regarding its central role in the com-
plement and coagulation pathways, MBL might turn out to be the
key protein in the remodeling phase of bone healing. If clearance of
apoptotic cells fails, this failure in remodeling the newly formed
callus will prevent the two fractured ends to approximate and
consolidate and may be an important mediator in the development
of non-union.26,32
6. Conclusion
The involvement ofMBLwithin the processes of complement and
coagulation is extensive. Regarding the central role of MBL in these
processes, a deﬁciency of this lectin may have a deﬁnitive role in the
non-union of fractures. This may be due to either an accumulation of
apoptotic cells that prevents the two fractured ends to approximate
and consolidate, or to a diminished scaffold of ﬁbrin molecules that
disturbs adequate fracture healing. We propose that functional MBL
genotyping may serve as a prognostic tool for the development of
non-union of a fracture. Early identiﬁcation of those patientswho are
at risk of developing a non-union can be helpful in the allocation of
additional treatment modules in order to prevent the formation of a
non-union. For example, in those patients with a deﬁciency of MBL,
commencing directly with extra internal or external stabilization
may be indicated. In addition, an MBL deﬁciency may be substituted
with either a plasma-puriﬁedMBL-product or a recombinant human
MBL-product, possibly in combination with the administration of
bonemorphogenetic proteins (BMP’s).33,34 Recent research including
a study population of MBL-deﬁcient patients demonstrated an up-
regulation of L-ﬁcolin and MASP-2, both proteins of the lectin
pathway.35 This up-regulation may compensate for the deﬁciency in
MBL blood levels and may be useful in the prevention of non-union.
MBL has a substantial role in the process of fracture healing and
its depletion may therefore be an important disease-modifying
factor in non-union of diaphyseal fractures. Early identiﬁcation of
a MBL deﬁciency is a requisite. The ﬁnding that a patient presenting
with a fracture has a concomitant deﬁciency of MBL may be a
prognostic parameter for the outcome of planned treatment.
Translational and clinical research is needed to clarify the exact role
of MBL in fracture healing and its value as a prognostic marker.
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